

Table S1. Characteristics of 69 HCL patients and BRAF mutation test results

PT No.	Dx	% of HCL	VH	Sex	Age at Dx	BRAF c.1799T>A (V600E)	BRAF c.1799T>A (AQ%)
BN30	HCL	95.0	VH1-18	M	37	Pos	83.5
BL47	HCL	94.1	VH3-7	M	50	Pos	95.4
BL46	HCL	92.2	VH4-39	M	44	Pos	72.0
BH05	HCL	91.1	VH3-30	M	50	Pos	30.7
L235	HCL	90.6	VH1-2	M	56	Pos	87.2
HH31	HCL	88.3	VH3-21	M	55	Pos	84.0
RC08	HCL	85.5	VH3-30	F	49	Pos	45.5
HH20	HCL	82.2	VH3-23	M	72	Pos	72.5
BN19	HCL	80.6	VH3-30	M	51	Pos	54.0
BH21	HCL	77.4	VH5-51	M	44	Pos	42.6
BH31	HCL	77.0	VH3-33	M	64	Pos	73.8
HH27	HCL	74.4	VH3-h	M	49	Pos	54.4
HH38	HCL	74.0	VH3-21	M	58	Pos	40.7
RB09	HCL	64.7	VH3-33	M	44	Pos	37.3
RD09	HCL	64.6	VH3-30	M	45	Pos	42.9
HH22	HCL	61.4	VH3-23	M	60	Pos	35.0
BH10	HCL	59.6	VH3-23	M	42	Pos	60.8
BL25	HCL	58.1	VH4-39	M	39	Pos	46.6
RC03	HCL	50.6	VH4-39	M	42	Pos	31.3
RC06	HCL	47.3	VH4-31	M	44	Pos	35.6
RC11	HCL	41.2	Unk	M	56	Pos	27.0
BN43	HCL	40.0	VH4-59	F	38	Pos	64.6
BL49	HCL	39.4	VH1-2/3-74	M	61	Pos	35.8
BL43	HCL	37.0	VH3-11	M	59	Pos	66.9
BH02	HCL	35.0	VH1-3	M	62	Pos	41.5
BL38	HCL	33.8	VH4-39	M	41	Pos	36.9
HH08	HCL	33.6	VH2-26	M	61	Pos	36.0
BL29	HCL	32.0	VH3-33	M	41	Pos	59.3
RD14	HCL	28.2	VH3-53	F	58	Pos	30.5
BH03	HCL	26.6	VH3-23	M	45	Pos	31.0
RC09	HCL	22.0	VH3-9	M	55	Pos	23.0
HH16	HCL	21.2	VH3-13	M	51	Pos	16.2
BH12	HCL	17.9	VH3-7	M	50	Pos	18.4
BL44	HCL	16.8	VH3-30	F	43	Pos	26.5
RC05	HCL	16.4	VH3-30	M	42	Pos	17.4
HC05	HCL	16.0	VH1-69	M	37	Pos	12.4
HH04	HCL	15.6	Unk	M	56	Pos	22.4
HH40	HCL	12.6	VH3-74	M	61	Pos	11.0
RD13	HCL	12.5	Unk	M	59	Pos	12.0
HH30	HCL	11.8	VH1-69	M	38	Pos	11.2
BH17	HCL	11.0	Unk	M	56	Pos	7.9
RD03	HCL	10.7	Unk	M	47	Pos	8.3*
RB07	HCL	59.0	VH3-48	M	37	Neg	3.2
RB04	HCL	42.7	VH3-23	M	62	Neg	4.0
RC04	HCL	28.5	VH3-15	M	47	Neg	6.7
BL15	HCL	19.4	Unk	M	35	Neg	3.3
RD15	HCL	19.1	VH2-70	M	34	Neg	6.7
BN52	HCL	19.0	VH4-39	M	56	Neg	4.5
BH18	HCL	92.6	VH4-34	M	61	Neg	3.8
HC08	HCL	90.5	VH4-34	M	72	Neg	3.0
BL42	HCL	77.8	VH4-34	M	84	Neg	3.5
HH14	HCL	12.9	VH4-34	M	54	Neg	3.4
BH34	HCL	12.5	VH4-34	M	60	Neg	3.1
RG06	HCLv	63.5	VH4-34	F	59	Neg	3.5
RG05	HCLv	59.2	VH4-34	F	57	Neg	3.3
BL18	HCLv	52.0	VH4-34	M	73	Neg	5.3
BH29	HCLv	48.5	VH4-34	M	59	Neg	2.6
BL26	HCLv	34.6	VH4-34	M	59	Neg	3.1
BH16	HCLv	24.4	VH4-34	M	56	Neg	3.9
BH28	HCLv	21.5	VH4-34	M	46	Neg	3.3
RG04	HCLv	12.9	VH4-34	M	78	Neg	3.4
BL14	HCLv	80.5	VH4-31	M	42	Neg	3.0
RG01	HCLv	73.1	VH6-1	M	41	Neg	3.3
BN42	HCLv	70.3	VH3-15	M	72	Neg	3.8
HH10	HCLv	48.9	VH1-18	M	44	Neg	3.2
RG08	HCLv	42.0	VH1-69	M	73	Neg	4.3
RG07	HCLv	41.0	VH3-30	M	84	Neg	3.6
BN16	HCLv	24.1	VH4-31	M	67	Neg	2.8
RG03	HCLv	21.1	VH3-9	F	53	Neg	4.0

* CD11c sorted cells was available and confirmed positive for BRAF V600E




Figure S1. Correlation of BRAF mutant allele quantification (AQ) with leukemia cell count (% WBC) in 42 BRAF mutant cases, 27 BRAF wild-type cases, and 24 normal peripheral blood controls